top of page
Search

Restorative Neuromodulation for Mechanical Low Back Pain: The Evidence and the Opportunity

yan88701
2 hours ago
3 min read

By Yesh Navalgund, MD, interventional pain consultant and advisor

Chronic low back pain without a surgical target is one of the most expensive and frustrating categories in spine care. Patients cycle through physical therapy, medications, and injections, often with short-lived relief. For a defined subgroup, restorative neuromodulation offers a different model: treat a mechanical, muscle-control problem rather than only modulating pain signals. As payment shifts toward function and durability, this category deserves attention from everyone in the pain and spine ecosystem.

The clinical rationale: the multifidus

The lumbar multifidus is a deep muscle that helps stabilize each segment of the lower spine. In some people with chronic low back pain, neuromuscular control of this muscle becomes impaired, the spine loses part of its dynamic stability, and a cycle of pain and further dysfunction follows. This is described as chronic mechanical low back pain associated with multifidus dysfunction.

Conventional neuromodulation, such as spinal cord stimulation, works mainly by altering pain signal processing. Restorative neurostimulation aims to restore muscle control so the spine can stabilize itself.

How ReActiv8 works

ReActiv8, from Mainstay Medical, is an implantable system that stimulates the medial branch of the L2 dorsal ramus, which innervates the lumbar multifidus, to restore multifidus activation (Reg Anesth Pain Med, 2025). ReActiv8 is FDA approved for adults with intractable chronic low back pain associated with multifidus muscle dysfunction who are not surgical candidates, and therapy is delivered in two 30-minute sessions a day.

The evidence

ReActiv8-B pivotal trial. A randomized, sham-controlled, double-blinded trial of 204 participants with refractory mechanical chronic low back pain and no indication for spine surgery, with long-term follow-up after the randomized phase.

Five-year follow-up (Gilligan et al., Neuromodulation, 2024), 126 participants completing the five-year visit:

  • Back pain fell from 7.3 to 2.4 on a 10-cm scale; 71.8% had at least a 50% reduction.

  • Oswestry Disability Index improved from 39.1 to 16.5; 61.1% improved by 20 points or more.

  • EQ-5D-5L quality of life improved from 0.585 to 0.807.

  • Of 52 participants on opioids at baseline with a five-year visit, 46% discontinued and 23% reduced intake.

  • Safety compared favorably with other neurostimulators for back pain, with no lead migrations observed.

A mixed-effects model accounting for missing data attenuated the completed-case results, but conclusions and statistical significance held.

Real-world UK data (Reg Anesth Pain Med, 2025): 42 patients across five UK sites; among 34 completing five years, pain fell from 7.0 to 3.2, disability from 46.6 to 26.1, and 62% were pain remitters (NRS of 3 or less). Device use declined over time, and lower use was associated with non-response, though causality could not be determined.

Mainstay has also reported that some ReActiv8-B participants had devices removed because their back pain resolved, which it cites as support for a restorative rather than purely palliative mechanism (Mainstay Medical).

Patient selection is the whole game

Outcomes depend on identifying the right patients: chronic, activity-limiting mechanical low back pain refractory to conservative care, evidence of impaired multifidus control (the pivotal trial required a positive prone instability test), no surgical indication, and pain that is primarily axial rather than radicular. Distinguishing this phenotype from facet-mediated, discogenic, or compressive pain is where programs succeed or fail.

What it means by stakeholder

  • Health systems and practices: building a restorative pathway requires diagnostic rigor, referral education, and outcome tracking. Remote Therapeutic Monitoring can support adherence, which the UK data suggest matters.

  • Payers: five-year function, quality-of-life, and opioid-use data are directly relevant to coverage and value assessment.

  • Device companies: durable outcomes data positions restorative therapies well under Medicare's upcoming Ambulatory Specialty Model, which measures function and avoidable procedures.

  • Investors: the category's growth depends on selection accuracy, referral pipeline development, and reimbursement durability.

  • Referring physicians: this is a potential option for patients with chronic axial low back pain who have exhausted conservative care and have no surgical target.

A note for patients reading this

Every implanted device carries risks, and individual results vary. If you think this type of therapy might apply to you, ask when you next visit your doctor.

Working together

I advise health systems, practices, device companies, and investors on neuromodulation strategy, including evidence review, patient-selection pathways, program launch, and outcomes measurement. If restorative neuromodulation is part of your plans, I would be glad to help.

This article is for general education and is not medical advice.

Sources

 
 
 

Recent Posts

See All

Comments

bottom of page